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Abstract Several distinct melanoma syndromes have been de-
fined, and genetic tests are available for the associated causative
genes. Guidelines for melanoma genetic testing have been pub-
lished as an informal Brule of twos and threes,^ but these guide-
lines apply to CDKN2A testing and are not intended for the
more recently described non-CDKN2A melanoma syndromes.
In order to develop an approach for the full spectrum of hered-
itary melanoma patients, we have separated melanoma syn-
dromes into two types: Bmelanoma dominant^ and Bmelanoma
subordinate.^ Syndromes in which melanoma is a predominant
cancer type are considered melanoma dominant, although other
cancers, such as mesothelioma or pancreatic cancers, may also
be observed. These syndromes are associated with defects in
CDKN2A, CDK4, BAP1, MITF, and POT1. Melanoma-
subordinate syndromes have an increased but lower risk of
melanoma than that of other cancer(s) seen in the syndrome,
such as breast and ovarian cancer or Cowden syndrome. Many
of these melanoma-subordinate syndromes are associated with
well-established predisposition genes (e.g., BRCA1/2, PTEN).
It is likely that these predisposition genes are responsible for the
increased susceptibility to melanoma as well but with lower
penetrance than that observed for the dominant cancer(s) in
those syndromes. In this review, we describe our extension of
the Brule of twos and threes^ for melanoma genetic testing. This
algorithm incorporates an understanding of the spectrum of
cancers and genes seen in association with melanoma to create
a more comprehensive and tailored approach to genetic testing.
Keywords Melanoma . Genetic testing . Inherited cancer
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1 Introduction
A small portion of melanomas (approximately 5–12%) occurs
in patients with a strong family history of melanoma [1, 2].
About 45% of these familial melanomas have been attributed
to inheritance of a mutation in a highly penetrant predisposi-
tion gene [3]. The 55% Bmissing inheritance^ is likely due to
the inheritance of lower-penetrance predisposition genes in
combination with inheritance of polymorphisms and/or shared
environmental exposures that predispose toward melanoma,
culminating in a familial pattern of melanoma inheritance. In
addition to this Bmelanoma-dominant^ pattern of inheritance,
melanoma can also be a Bsubordinate^ cancer in the context of
other cancer syndromes. For example, family members with
Cowden syndrome, Li Fraumeni syndrome, and some cancer-
specific syndromes such as breast and ovarian cancer syn-
drome have a poorly-defined but elevated risk of melanoma.
The genes associated with these other types of cancer syn-
dromes (e.g., phosphatase and tensin homolog (PTEN), tumor
protein p53 (TP53), breast cancer 1 and 2 (BRCA1/2),
xeroderma pigmentosum (XP A-G)) are therefore acting as a
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lower-penetrance melanoma gene in the context of that syn-
drome [1]. Within the melanoma-dominant syndromes caused
by cyclin-dependent kinase inhibitor 2A (CDKN2A), and
BRCA1-associated protein 1 (BAP1), pathogenic mutations
in these genes cause increased incidence of other cancer types
(e.g., pancreatic cancer, neurological tumors, renal cell carci-
noma, mesothelioma) but with lower penetrance than melano-
ma [2].
As cancer predisposition syndromes and their associated
genes are clarified, significant, previously unappreciated over-
lap is being identified: melanoma genes can be associatedwith
other cancer types and other cancer predisposition genes can
increase the risk of melanoma.
This overlap has major implications for genetic testing
strategies. Especially in an era when reasonably priced
multi-gene panel tests are available, it no longer seems appro-
priate to offer genetic testing to high-risk melanoma patients
for only CDKN2A when other genes are known to cause
melanoma-dominant syndromes. In addition, there should
likely be special consideration given to families that fail to
meet the genetic testing criteria for a melanoma-dominant
syndrome yet also have other cancers suggestive of a
Bmelanoma-subordinate^ cancer syndrome. For example,
consider a family with first- and second-degree relatives that
have had two melanomas, a breast cancer at age 51 and a
prostate cancer at age 42. Although this scenario does not
meet formal criteria for CDKN2A, BRCA, or TP53 genetic
testing, failure to diagnose an actionable mutation in this fam-
ily could lead to inadequate cancer screening. In addition,
because different subspecialty providers often care for family
members with different cancer types, the benefit of additional
cancer screening beyond that recommended for a single can-
cer might not be recognized without identification of a unify-
ing genetic cancer predisposition.
Genetic testing of appropriate individuals and the tailored
follow-up recommendations that ensue can improve early de-
tection, reduce mortality, and enhance compliance with pre-
vention recommendations [4, 5]. Furthermore, if the highest-
risk individuals are selectively screened and treated before
expensive systemic therapies are required, costs can be re-
duced and productive years of life can be increased.
Numerous panel tests are now commercially available
allowing for single pass screening of tumor susceptibility
genes at about the same cost that was previously paid for
single-gene testing, making panel testing an attractive option
for melanoma families. Given this and the increasing recogni-
tion of cancer syndromes that include melanoma, we offer a
comprehensive, tailored cancer gene assessment tool for fam-
ilies with a hereditary pattern of cancer that includes melano-
ma. This article will focus on how to utilize risk assessment
strategies to identify appropriate candidates for genetic testing,
identify genes for a tailored panel test, interpret genetic test
results, and utilize results to make practical clinical
management recommendations. It will also highlight how im-
proved genetic testing technology can be applied now, with
rational suggestions for keeping pace with these advances in
clinical practice. By taking this approach, it is possible to
incorporate more comprehensive technology into patient care
(without substantially increasing cost), advance our under-
standing of the spectrum of cancers observed in association
with predisposition genes, and provide appropriate advice to
patients that can be augmented as medical knowledge
increases.
2 Approach to minimize the caveats of panel testing
In addition to benefits of melanoma genetic testing, there are
also costs associated with genetic testing and heightened sur-
veillance, including increased frequency of biopsies and other
procedures. For this reason, it is critical that individuals are
pre-screened to identify those with a reasonable probability of
carrying an actionable mutation. It is equally important to
provide accurate risk statistics to patients who undergo genetic
testing, and this includes acknowledgment that some data is
incomplete and thus no change in management is yet recom-
mended. It is essential that the counselor and patients feel
comfortable with the possibility of getting unclear results
returned to them, and this should be included as part of the
informed consent process.
Another caveat of panel testing is that follow-up and man-
agement recommendations for some gene mutations are not
well developed. Tomitigate this effect, our practice is to report
only genes with a strong clinical association. Genes that have
limited evidence should be used for research purposes only.
Research-related results should be reported after more defini-
tive guidance is available, similar to reports for variants of
uncertain significance. The reportable genes, as well as some
of their corresponding cancers, have been listed in Table 1.
By collaborating with our patients to perform tests that are
currently in the research realm and counseling them on the
uncertain significance of the results as our knowledge of
genotype-phenotype relationships improves, we can simulta-
neously move the field forward faster both clinically and sci-
entifically. It is important to note that if mutations that have
only preliminary evidence for pathogenicity are included in
the testing process, it will require additional genetic counsel-
ing to assure that the patient understands the equivocal nature
of mutations found in these genes, similar to the discussion
regarding variants of unknown significance (VUS). This ad-
ditional counseling effort may not be possible and/or advis-
able in some situations or for some patients. In this case, it
may be best for those providers and patients to utilize a single-
gene or panel test that does not contain research or preliminary
genes, at the discretion of the provider.
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3 Background: melanoma predisposition genes
As stated above, several melanoma predisposition genes have
been identified to date. The most common is the CDKN2A
gene locus, which is involved in approximately 20–40% of
large, high-risk families [6, 7]. The CDKN2A gene locus en-
codes twomelanoma predisposition genes with different func-
tions: CDKN2A/p16, a tumor suppressor that imposes control
Table 1 Reportable genes and














APC • [57] • [56]




BMPR1A • [64] • [64]
BRCA1 • [60] • [53] • [54] • [53]
BRCA2 • [60] • [53] • [54] • [53]
BRIP1 • [67] • [67]
CDH1 • [68] • [69]
CDK4 • [23] • [23]
CDKN2A • [2] • [60]
CHEK2 • [70] • [71] • [72]
DICER1 • [73]






MLH1 • [60] • [78] • [79] • [80]
MSH2 • [60] • [78] • [79] • [80]




PALB2 • [60] • [86]




PTEN • [84] • [49] • [84]
RAD50 • [88] • [89]
RAD51C • [90]
RAD51D • [91]
SMAD4 • [64] • [64]
SMARCA4 • [92]
STK11 • [60] • [93] • [93] • [93]
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through the retinoblastoma (Rb) pathway [8, 9], and
CDKN2A/ARF, another tumor suppressor that functions
through the p53 pathway [10]. Families that carry a pathogen-
ic mutation in CDKN2A have an increased risk for melanoma,
pancreatic cancer, and perhaps neurological tumors like astro-
cytoma [6, 11]. Individuals in these families frequently, but
not always, have a large number of atypical moles. A substan-
tially increased number of atypical moles in the setting of a
CDKN2A mutation has been termed familial atypical mole
and malignant melanoma syndrome (FAMMM), although it
is also called the familial melanoma and pancreatic cancer
syndrome (FMPC) or the familial atypical multiple mole
melanoma-pancreatic carcinoma syndrome (FAMMPC), be-
cause of the increased risk of pancreatic cancer [12–18].
Clinical genetic testing for CDKN2A mutations has been
widely available since the mid-2000s, and guidelines for use
of this test were published in 2009 and are detailed below [19].
Although CDKN2A/p16 is the most common and best
characterized melanoma-dominant predisposition gene, sever-
al additional, less common predisposition genes are associated
with heritable risk for melanoma and other cancers including
alternate reading frame (CDKN2A/ARF) [20], cyclin-depen-
dent kinase 4 (CDK4) [21–23], telomerase reverse
transcriptase (TERT) [24, 25], protection of telomeres 1
(POT1) [26, 27], adrenocortical dysplasia (ACD) [28],
telomeric repeat-binding factor-2 (TERF2) interacting protein
(TERF2IP) [28], breast cancer gene 1 (BRCA1)-associated
protein 1 (BAP1) [29–34], and microphthalmia-associated
transcription factor (MITF) [35–39]. Most recently, the tumor
suppressor BAP1 has been identified as the causal gene in a
tumor predisposition syndrome including, among others,
atypical Spitz tumors, cutaneous and uveal melanoma, meso-
thelioma, and clear cell renal carcinoma. Deleterious muta-
tions in these genes lead to a disproportionately high risk of
melanoma development relative to other cancers.
Clear guidelines for genetic testing of these non-CDKN2A
genes have not been published, despite the availability of
these tests in several clinically certified laboratories.
Informally and in research protocols, family members that
meet the criteria for CDKN2A/p16 testing have been tested
at the entire locus, including the CDKN2A/ARF component
and promoter regions. Families shown to bemutation negative
at the CDKN2A locus are sometimes tested reflexively for the
most common CDK4 mutation site, Arg24. This CDKN2A/
p16 binding site (Arg24) is required for CDK4 inhibition by
CDKN2A/p16 and mutation transforms the protein into an
unregulated oncoprotein [40], making single site testing of
this codon a reasonable consideration.
Melanoma is also observed at higher-than-expected rates in
other hereditary cancer syndromes arising from germline muta-
tions in tumor susceptibility genes (melanoma-subordinate syn-
dromes). More specifically, increased risk for melanoma is seen
in xeroderma pigmentosum (multiple XP genes) [41], Cowden
syndrome (PTEN mutations) [42], Li Fraumeni syndrome
(TP53 mutations) [43], and possibly others. However, guide-
lines for melanoma screening and genetic testing are unclear in
most of these syndromes. When features of these syndromes
are identified, it is important to include counseling about mel-
anoma prevention and follow-up recommendations as part of
their genetic counseling session. Furthermore, use of genetic
panel testing for a variety of syndromes, including those with
a predominance of melanoma, will begin to refine the constel-
lation of cancers seen in association with various mutations.
4 Identification and selection of melanoma genetic
testing candidates
In 2009, international guidelines were published suggesting
that individuals with an estimated 10% or greater pre-test
probability of carrying a mutation in CDKN2A should be re-
ferred for genetic counseling [19]. However, accurate esti-
mates of pre-test probabilities of mutation carriage were com-
plicated by the interdependence upon ethnicity and geography
that underlie a general population’s risk for melanoma. These
guidelines suggest that candidacy for counseling and
CDKN2A testing be based on the number of (1) invasive pri-
mary melanomas in the identified patient (proband), (2) inva-
sive melanomas in blood relatives, and (3) the numbers of
pancreatic cancers in the proband or blood relatives. The min-
imum number of cancers required to establish candidacy is
based on the baseline population rates of the family’s place
of residence. This rationale posits that individuals with a high
genetic risk for melanomawould have substantially moremel-
anomas (or melanomas plus pancreatic cancer) than the gen-
eral population in their area. For example, in areas of
intermediate-to-high population risk of melanoma such as
the USA or Northern Europe (with estimated, age-
standardized rates ≥10 per 100,000), individuals or families
with a total of three or more primary melanomas (or combi-
nations of melanoma and pancreatic cancer) would be referred
for genetic counseling. However, in areas with lower melano-
ma incidence (rate <10 per 100,000), such as Italy, Spain, or
France, development of two or more melanomas (or melano-
ma and pancreatic cancer combinations) in an individual or
family would be referred for counseling. Use of this Brule of
twos or threes^ criteria for melanoma genetic testing leads to
approximately 10% positive results for CDKN2A mutation. It
is important these guidelines not be viewed as absolute
Brules^ that replace clinical judgment in individual circum-
stances. For instance, it is unclear how environment, other
prognostic risk factors such as the hair, eye, and skin color,
and/or ethnicity contribute to the overall risk in individuals
with CDKN2A (or other melanoma gene) mutations.
Furthermore, in Italy, it has been determined that in situ mel-
anomas can be included in the Brule of two^ criteria applied to
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the Italian population [44, 45], while in the USA, this data is
based on invasive melanomas and individuals with melanoma
in situ should be evaluated on an individual basis.
As described above, many additional cancer susceptibility
genes have been identified that are associated with an in-
creased risk of melanoma (melanoma-subordinate
syndromes) and other cancers. In this paper, we update the
Brule of twos and threes^ that takes other non-melanoma can-
cer types into consideration. To accomplish this task, we have
created a simplified scoring system that identifies individuals
or families that have a pattern of cancer development suspi-
cious for germline inheritance of a pathogenic mutation. In
this assessment tool, a score of 3 is required as the threshold
with which to proceed with genetic testing, effectively creat-
ing a universal Brule of threes.^ To create this tool, we have
incorporated criteria from several sources. First, we have
accounted for high and low melanoma geographic areas by
designating one point in moderate or high-incidence areas and
1.5 points in low-incidence areas. Second, we have included
guidelines used in cancers other than melanoma that, in their
own right, would fulfill criteria for genetic testing but also
have a family member with melanoma. These findings count
as one point; however, it is important to note that occurrence
of these findings in the absence of melanoma would prompt
consideration of genetic testing. Third, we account for clinical
findings consistent with the melanoma-dominant tumor syn-
drome caused by a BAP1mutation. Lastly, we have accounted
for a high incidence of cancers in a single individual or family
that do not otherwise meet criteria for genetic testing. The
original Brule of twos and threes^ was based on finding
criteria that would provide at least a 10% pre-test probability
of finding an actionableCDKN2Amutation. Ideally, wewould
apply this same pre-test probability for every permutation of
melanoma and other melanoma-subordinate syndrome cancer
types. However, this level of data does not yet exist. In the
absence of hard data, our institutions have felt that it is not
appropriate to consider all other cancers equal with respect to
fulfilling the rule of three. There are three cancers in
melanoma-subordinate syndromes with a greater lifetime
probability of developing invasive cancer than melanoma it-
self (approximately ≥4–5%), including prostate, breast, and
colon. In the case of these cancers, assuming they do not fulfill
other requirements for consideration as a genetically associat-
ed cancer, our centers Bcount^ two of these cancers as one
point in meeting the Brule of threes^ criteria. For example, if
an individual in the USA with melanoma has one second-
degree blood relative with melanoma and one with breast
cancer, then she would not fulfill the criteria unless the indi-
vidual with breast cancer was of a younger age, of male gen-
der, or otherwise highly suspicious for having a genetic cause.
However, if there were two breast cancer occurrences in ad-
dition to the two melanoma cases, then the Brule of threes^
would apply (Table 2).
5 Choosing the appropriate family member
for genetic testing
Whenever a high-risk family has been identified, it is impor-
tant to select an appropriate family member for genetic testing.
Ideally, a member of the family that has had cancer should be
tested first and, if possible, the youngest member with cancer
or the member with the most dramatic hereditary pattern. This
maximizes the chances of identifying an actionable mutation,
although it is also conceivable that the individual who has
been tested has a sporadic cancer in the context of a familial
syndrome. For this reason, if the family history is extremely
compelling for having a cancer syndrome but the individual
that was tested does not carry a mutation, it may be important
to test a second individual in the family. It is not generally a
good practice to test an unaffected individual in the family
because a negative test could reflect the fact that they are a
non-carrier in the family, rather than reflecting the fact that the
family does not carry a mutation.
6 Tailored genetic testing based on family history
In the following section, we detail how our institutions design
a personalized genetic panel based on the personal and family
history of a suspected hereditary cancer syndrome. This algo-
rithmic approach is summarized in Fig. 1. Once an individual
or family has met criteria for genetic testing and has received
genetic counseling with informed consent, our centers create a
tailored panel test that includes the genes that are most likely
to be mutated, based on the other cancer types observed in the
pedigree. The rationale for these choices is described below.
6.1 Genetic testing for melanoma-dominant syndromes
Any patient or family that meets the updated Brule of threes^
should be considered a candidate for genetic testing. If mela-
noma is the only cancer in a pedigree, then to meet the thresh-
old of genetic testing, a pedigree should have three primary
melanomas in first- or second-degree relatives in areas with a
high melanoma incidence or two primary melanomas in a
low-incidence area. This melanoma panel should include
BAP1, CDK4, and CDKN2A. Genes for which risk has not
been established but for which studies suggest an elevated risk
include MITF and POT1 and we recommend including these
in the melanoma panel. Genes with a preliminary clinical as-
sociation include ACD, BRCA1, BRCA2,MC1R, PTEN, RB1,
TERT (with promoter), TERF2IP, and TP53 which may be
included for research purposes (Fig. 2).
Rarely, our institutions may test for CDKN2A or BAP1 as a
single test, particularly if other cancers, such as pancreatic
cancer or astrocytoma in the family, strongly suggest
CDKN2A is the offending gene. Similarly, if the family has
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cutaneous melanomas, uveal melanoma, renal clear call carci-
noma, mesothelioma, or paraganglionoma, then a BAP1 test
may be sufficient (Fig. 1). It should also be noted that single-
gene testing may be done in cases where a specific mutation in
a cancer susceptibility gene has been identified in a pedigree
and a relative requests testing to determine carrier status.
6.2 Genetic testing for melanoma-dominant
and melanoma-subordinate syndromes that also
demonstrate pancreatic cancer
Co-occurrence of pancreatic cancer and melanoma usually oc-
curs in the setting of aCDKN2Amutation. However, pancreatic
Table 2 Melanoma cancer syndrome assessment tool
Cancer type Criteria Points per occurrence
Melanoma Occurrence in melanoma proband, first- or second-degree relativea 1 or 1.5b
Astrocytomac Occurrence in melanoma proband, first- or second-degree relative 1.5
Breast Occurrence in proband, first- or second-degree relative under 45 years of age 1d
Occurrence of bilateral or triple negative breast cancer in proband, first- or second-degree relative 1d
Occurrence in male gender 1d
Colon Occurrence in proband or first-degree relative that occurred under 50 years of age 1d
Proband has had more than five adenomatous polyps occurring under 50 years of age 1d
Ovarian Occurrence in proband, first- or second-degree relative 1
Pancreaticc Occurrence in proband, first- or second-degree relative 1.5
Prostate Proband has had metastatic prostate cancer and/or had a Gleason score >7 at diagnosis 1d
High frequency At least two occurrences of breast, colon, or prostate cancer in melanoma proband, first-
or second-degree blood relatives that do not meet the criteria above
1
BAP1 cancer syndrome Occurrence in proband or first-degree relative of uveal melanoma, paraganglioma,
mesothelioma, atypical Spitz tumors or clear cell renal carcinoma
1.5/cancer type
Perform genetic testing 3 or more
a First-degree relatives include parents, siblings, and children; second-degree relatives are blood relatives that include grandparents, grandchildren, aunts,
uncles, nephews, nieces, or half-siblings
b 1 point in moderate or high melanoma incidence areas and 1.5 points in low-incidence areas. Regions with an estimated, age-standardized incidence
rate of <10 per 100,000 is considered low incidence. See GLOBOCAN online for current rates
c Pancreatic cancer and astrocytoma are scored 1.5 due to increased incidence in melanoma-dominant syndromes caused by a CDKN2A mutation
d The criteria listed suggest a hereditary pattern that may fulfill standard criteria for single-gene or cancer-specific panels without association with
melanoma. Anyone or any family with these findings should be considered for genetic testing regardless of their melanoma status. However, if the
criteria are met in the context of melanoma, we test additionally for melanoma genes
Only Melanoma
+/- Pancreatic OR
+/- astrocytoma or other 
neurological tumor
Melanoma
+ Uveal Melanoma OR
+ Paraganglioma OR
+ Mesothelioma OR
+ Clear Cell Renal Carcinoma
+ Atypical Spitz tumors









Overview of Genetic Testing in Melanoma Dominant and Subordinate Cancer Syndromes
If negative
If negative
Melanoma Dominant Melanoma Subordinate
If constellation of suspicious 
clinical findings, then consider




Fig. 1 Overview of genetic testing in melanoma-dominant and
melanoma-subordinate cancer syndromes. This algorithm details
navigation of genetic testing based on family history. It is also an option
to proceed directly to panel testing. FAMMM familial atypical multiple
mole melanoma syndrome. The left side of the figure depicts syndromes
that contain melanoma as the dominant cancer in the syndrome whereas
the right side of the figure depicts other cancer syndromes that contain
melanoma as a subordinate cancer
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cancer also occurs in melanoma-subordinate syndromes
(e.g., BRCA2). When pancreatic cancer is present in a family, it
is reasonable to assess for genes that carry a high risk of pancre-
atic cancer. Genes that carry greater than a twofold increase in
pancreatic cancer risk include APC, BRCA2, CDKN2A,
EPCAM, MLH1, MSH2, and STK11. Genes for which risk has
not been established but for which studies suggest an elevated
risk include ATM, BMPR1A, BRCA1, MEN1, MSH6, PALB2,
PMS2, SMAD4, TP53, TSC1, and TSC2 and we recommend
including these in the primary panel. Preliminary evidence genes
that remain in the research realm includeCDH1,CDK4,FANCC,
and PALLD. Chronic pancreatitis genes may be added if there is
suspicious personal or family history of pancreatitis and include
CASR, CFTR, CTRC, PRSS1, and SPINK1 (Fig. 2).
6.3 Genetic testing for melanoma-subordinate syndromes
with breast cancer
Because breast cancer is relatively common (incidence rate of
12.4% in the USA [46]), we recommend that in order to be
included toward fulfillment of the Brule of threes,^ breast can-
cer must have one or more of the following features: (1) one of
the melanoma patients or a first- or second-degree relative has
had breast cancer under 45 years of age, (2) at least one mela-
noma patient or first-degree relative has had triple negative or
bilateral breast cancer under 60 years of age, or (3) there is a
breast cancer occurrence in a male patient, or (4) there are two
or more instances of breast cancer in addition to melanoma in
the pedigree. In our centers, any of these four breast cancer
criteria counts as one point toward the Brule of threes^ to fulfill
the melanoma testing criteria. It is important to note that if the
pedigree was to havemore than one of the breast cancer criteria,
it would fulfill the criteria for breast cancer genetic testing in its
own right, but if a melanoma was also found in the pedigree, it
would be reasonable to include melanoma genes in the panel,
particularly if traditional breast cancer genes proved to be neg-
ative. To account for a high frequency of breast cancer, we also
assign a single point to two occurrences of breast cancer at any
age in the proband or in first- or second-degree blood relatives
that do not otherwise satisfy the above criteria.
If a family is a good candidate for testing based on the
occurrence of both melanoma and breast cancer, then both mel-
anoma and breast cancer genes should be tested. In addition to
the melanoma primary and research panels, a breast panel
would include testing for the following cancer genes that have
a minimum twofold increase in breast cancer risk: ATM,
BRCA1, BRCA2, CDH1, CHEK2, NBN, PALB2, PTEN, and
STK11. Genes that have a strong clinical association but no
relative risk statistics to our knowledge include BARD1,
BRIP1, NF1, RAD50, and TP53. In addition to these genes that
have been confirmed as actionable, preliminary evidence exists
for AKT1, FAM175A, FANCC, MRE11A, MUTYH, PIK3CA,
RAD51C, RAD51D, RINT1, SDHB, SDHD, and XRCC2 and
these could be collected for research purposes (Fig. 2).
6.4 Genetic testing for melanoma-subordinate syndromes
with prostate cancer
Prostate cancer is similar to breast cancer with respect to hav-
ing a relatively high incidence of 14.3% in the general
Melanoma Dominant or Subordinate Syndrome Panel 
BAP1, CDK4, CDKN2A, MITF, POT1 
ACD, BRCA1, BRCA2, MC1R, PTEN, RB1, TERF2IP, TERT (promoter) 
TP53 
Pancreatic Cancer Panel 
APC, ATM, BMPR1A, BRCA1, BRCA2, CDKN2A, 
EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, 
PMS2, SMAD4, STK11, TP53, TSC1, TSC2  
CDK4, FANCC , PALLD  
If pancreatitis history, then add  
CASR, CFTR, CTRC, PRSS1, and SPINK1 
 
Colon Cancer Panel 
APC, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, 
GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, 
POLD1, POLE, PTEN, SMAD4, STK11, TP53 
ATM, BLM, BUB1B, ENG, FLCN, GALNT12, 
MLH3 
 
Prostate Cancer Panel  
BRCA1, BRCA2, CHEK2, HOXB13, MLH1, 
MSH2, MSH6, NBN, PMS2,TP53 
ATM 
Patient with score of 3 or greater  
on Melanoma Cancer Assessment Tool  
Perform melanoma primary gene panel 
Consider adding research panel after counseling patient.  
If point obtained in other cancer type,  
then add corresponding organ specific panel. 
Ovarian Cancer Panel 
BRCA1, BRCA2, BRIP1, DICER1, EPCAM, 
MLH1, MSH2, MSH6,  NF1,  PMS2, PTEN, 
RAD50, RAD51C, RAD51D, SMARCA4, STK11, 
TP53 
AKT1, BARD1, CDC73, CDH1, CHEK2, 
FAM175A, FANCC, MRE11A, MUTYH, PALB2, 
PIK3CA, POLD1, RAD50, RINT1, SDHB, SDHD, 
XRCC2  
+ 
Breast Cancer Panel 
ATM, BARD1, BRCA1,BRCA2, BRIP1, CDH1, 
CHEK2, NBN, NF1, PALB2, PTEN, RAD50, 
STK11, TP53 
AKT1, FAM175A, FANCC, MRE11A, MUTYH, 
PIK3CA, RAD51C, RAD51D, RINT1, SDHB, 
SDHD, XRCC2 
Fig. 2 Tailored genetic testing recommendations. If a patient has a score of 3 or greater, then a genetic panel should be tailored to the family history.
Genes listed in gray should be tested in the research realm after counseling the patient on the risks and benefits
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population. For this reason, we feel it is important that in order
to count as a point toward the Brule of threes^ criteria for
genetic testing, one or more of the following prostate cancer
criteria be met: (1) one of the melanoma patients has also had
metastatic prostate cancer and/or had a Gleason score >7 at
diagnosis or (2) at least two family members have had prostate
cancer. In addition to having the melanoma panel, the addi-
tional reportable prostate gene panel could include BRCA1,
BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, NBN,
PMS2, and TP53. Preliminary evidence genes include ATM
(Fig. 2).
6.5 Genetic testing for melanoma-subordinate syndromes
with colon cancer
Just as with breast and prostate, colon cancer has a higher
incidence rate of 4.4 and 4.7% for women and men, respec-
tively [46]. Therefore, to be counted as a point toward fulfill-
ment of the Brule of threes,^ the individual or family should
have one or more of the following colon cancer findings: (1)
one or more of the melanoma patients or one or more of the
first-degree relatives should also have had colon cancer under
50 years of age, (2) one of the melanoma patients should have
a history of five adenomatous polyps under the age of 50, or
(3) at least two occurrences of colon cancer in blood relatives.
The primary gene panel for a syndrome with melanoma and
colon cancer includes the melanoma genetic panel and genes
that have at least a twofold increase in colon cancer risk in-
cluding APC, BMPR1A, CDH1, EPCAM, GREM1, MLH1,
MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, and
TP53. Genes that have a strong clinical association also in-
clude AXIN2, CHEK2, POLD1, and POLE. The additional
preliminary evidence (or research) panel could include ATM,
BLM, BUB1B, ENG, FLCN, GALNT12, and MLH3 (Fig. 2).
6.6 Genetic testing for melanoma-subordinate syndromes
with ovarian/uterine cancer
Ovarian and uterine cancers fall into a much lower incidence
category than breast, prostate, and colon, showing an inci-
dence of 1.3% for ovarian and 0.8% for uterine. Ovarian and
uterine cancers are typically categorized as part of another
cancer syndrome, such as the breast and ovarian cancer syn-
drome or Lynch syndrome. In these cases, certain criteria for
these cancers are known to be associated with the hereditary
syndromes and are utilized to fulfill the threshold for genetic
testing in a family with melanoma. The occurrence of ovarian
or uterine cancer in the family counts as one point toward the
Brule of threes.^ In these cases, both melanoma and ovarian
(or uterine) genes should be included in the primary panel test.
Genes that have a minimum of a twofold risk increase in
ovarian cancer include BRCA1, BRCA2, BRIP1, DICER1,
EPCAM, MLH1, MSH2, PMS2, PTEN, RAD51C, RAD51D,
SMARCA4, and STK11. Genes with a strong association but
no relative risk calculations includeMSH6, NF1, RAD50, and
TP53. Given the increased incidence of uterine cancer in
Lynch syndrome, melanoma families with uterine cancer
should have the addition of colon cancer-associated genes,
including APC, AXIN2, BMPR1A, GREM1, MUTYH,
POLD1, POLE, and SMAD4. Preliminary evidence genes
could include AKT1, BARD1, CDC73, CDH1, CHEK2,
FAM175A, FANCC, MRE11A, MUTYH, PALB2, PIK3CA,
POLD1, RAD50, RINT1, SDHB, SDHD, and XRCC2 when
ovarian cancer is identified in the family and the colon re-
search panel when uterine cancer is identified in the family.
6.7 Genetic testing for classic cancer syndromes that
include melanoma
Several cancer syndromes include a wide spectrum of cancers,
including melanoma. Although, not all the syndromic mani-
festations are accounted for in our cancer assessment tool,
suspicion should be raised when these features arise in a he-
reditary manner.
Patients with xeroderma pigmentosum (XP genes) have a
greatly increased risk of non-melanoma skin cancer and a
greater than 2000-fold risk of melanoma. [47]. Suspicion for
this mutation should be raised in any child that develops cu-
taneous cancers within the first decade of life.
It is reasonable to suspect Lynch syndrome in any patient who
develops melanoma in the context of the cancers arising from
defects in the mismatch repair enzymesMLH1,MSH2, EPCAM,
MSH6, and PMS2, including colon cancer and cancers of the
endometrium, small intestine, ureter/uterus, or renal pelvis.
Analysis of a Lynch syndrome registry has observed melanoma
in patients with pathogenic mutations in these mismatch repair
enzymes; however, the increased incidence was not found to be
statistically significant [48]. Cowden Syndrome (CS) arises from
a pathogenic mutation in the PTEN gene. CS is a multiple
hamartoma syndrome with a high risk for benign and malignant
tumors of the thyroid, breast, colon, and endometrium. Affected
individuals usually have macrocephaly and a variety of skin
lesions including trichilemmomas and papillomatous papules.
Consensus diagnostic criteria for CS have been developed [49].
There is an evidence-based clinical scoring system available on-
line to assist in selecting patients for genetics referral and PTEN
testing [50]. The CS scoring system has been shown to be more
accurate than the National Comprehensive Cancer Network
(NCCN) diagnostic criteria [51]. The lifetime risk for cutaneous
melanoma is estimated at more than 5%.
Germline mutation carriers of TP53 have a substantial life-
time risk for a variety of cancers including childhood cancers
and multiple primary cancers. Classically Li Fraumeni syn-
drome (LFS) families have a history of childhood leukemias,
sarcomas, adrenal cortical carcinomas, and brain tumors and
pre-menopausal breast cancers. Genetic testing should be
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considered for any individual diagnosed with a cancer at a
younger age than normally expected or with multiple primary
cancers. Increased rates of melanoma and non-melanoma skin
cancers have been reported in families with LFS [52]. If a
family seems to be falling into one of the classic cancer syn-
dromes, then it makes sense to extend testing to other gene
subsets reflexively if the initial testing is negative.
Alternatively, if a particular cancer, such as melanoma, ap-
pears to be overrepresented, it would be reasonable to include
the genes for that cancer in the panel.
7 Alternative genetic testing strategies
A reasonable alternative to the tailored approach discussed
above is to test for all known cancer predisposition genes, with-
out discriminating based on the profile of cancers observed in
the family. This approach may not be substantially more ex-
pensive and may detect genetic causes that were not expected
based upon the cancers observed in the family. There are sev-
eral large cancer panels available, but unfortunately, none of
these include all the potential melanoma genes. Table 1 lists
all of the currently known genes that have been strongly asso-
ciated with a cancer predisposition syndrome, along with a
designation for the cancer with which it has been associated.
By including all of these genes in a single panel, every patient
may be treated the same without risk of missing a candidate
gene. However, with larger numbers of genes tested, the risk of
an irrelevant mutation or VUS being identified will increase
and complicate the genetic test reporting process.
Exome sequencing is another alternative approach.
Although whole exome and whole genome sequencing is per-
formed regularly on a research basis, the large numbers of
variants of uncertain significance and the number of unantic-
ipated actionable mutations make reporting extremely diffi-
cult. It is likely that these methods will eventually be applied
to clinical genetic predisposition testing, but at present, it re-
mains in the research realm for melanoma at our institutions.
8 Tailored follow-up and management
recommendations
Patients who have a family history concerning for a hereditary
cancer syndrome or who have had an actionable mutation
identified should be screened for associated cancers. In the
USA, screening recommendations for mutation carriers are
outlined in the NCCN Clinical Practical Guidelines in
Oncology (NCCN Guidelines) or put forth by expert opinion
consortiums. In the following paragraphs, we highlight these
recommendations. These recommendations should be applied
when one of these cancer types is seen in a melanoma-
dominant or melanoma-subordinate syndrome and also when
a gene is identified that is known to cause one of these
syndromes.
8.1 Melanoma screening recommendations
In melanoma-dominant or melanoma-subordinate pedigrees
or in individuals carrying a BAP1, CDK4, CDKN2A, MITF,
or POT1 mutation, individuals should be educated on the im-
portance of melanoma prevention and early detection. These
individuals should be instructed on photoprotection and
monthly self-skin screening examinations and should receive
a regular skin screening examination by a medical profession-
al. The frequency of examination by a health care provider
should be tailored to account for the melanoma status and the
difficulty of the examination, with higher-risk individuals re-
ceiving more frequent examinations ranging from every 3 to
12 months. If the individual has a personal history of melano-
ma, examinations should be in accordance with NCCN guide-
lines. If an individual has a large number of atypical nevi, it
may be important to increase the frequency of appointments to
3–6 months to enhance surveillance. Children should begin
self-screening as early as possible and provider-based screen-
ing should be initiated around the time of puberty. Monitoring
these individuals with longitudinal photography and digital
dermoscopy is helpful. A reduced threshold for biopsies of a
suspicious lesion is reasonable in these patients. Annual
screening for uveal melanoma, mesothelioma, and renal can-
cer should be considered for carriers of BAP1 germline muta-
tions [33].
8.2 Breast and ovarian screening recommendations
Hereditary breast cancer genes can be classified in three cate-
gories. High-risk breast cancer genes are those associated with
a fourfold relative risk. Moderate risk breast cancer genes are
associated with a lifetime risk of twofold, with the risk being
modifiable by family history. For the preliminary evidence
breast cancer genes, the lifetime risk has not been defined,
and therefore, estimation of risk is based solely on family
history using the Claus tables or Tryer-Cuzick model.
The cornerstone of management is earlier and more fre-
quent surveillance. For womenwho have high-risk breast can-
cer genetic mutations, breast awareness with self-breast exams
and clinical breast exams is recommended starting at age 18.
Imaging may begin as early as age 20 for TP53 mutation
carriers or age 25 for BRCA1 and BRCA2 mutation carriers.
Because of the concern for lifetime radiation exposure associ-
ated with mammograms starting at such a young age, breast
MRI is the imaging modality of choice between 20 and 30.
Mammograms alternating with MRI with contrast every
6 months are recommended starting at age 30. Consideration
of risk-reducing mastectomy (RRM) is an option for women
who have mutations in risk genes conferring a 50% or greater
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lifetime risk for breast cancer or have a mutation in a moderate
risk gene with significant family history.
If a woman has a mutation in a gene associated with an
increased risk for ovarian cancer, the option of a salpingo-
oophorectomy (RRSO) should be discussed between 35 and
40 years of age and upon completion of child bearing [53]. If a
patient decides to forego RRSO, then transvaginal ultrasound
and monitoring of CA-125 can be considered to monitor for
ovarian cancer onset; however, this has not been shown to be
sufficiently sensitive or specific to warrant recommendation.
8.3 Prostate cancer screening recommendations
Guidelines for patients with a high-risk prostate cancer muta-
tions have not been established by the NCCN; however, recent
results from the IMPACT study have shown that the positive
predictive values of prostate serum antigen (PSA) of 3.0 ng/mL
are higher in patients with a high-risk genetic mutation com-
pared to controls and that the former is more likely to have an
intermediate or high-risk for disease [54]. They thus state it is
reasonable to start with a baseline PSA and digital rectal exam
(DRE) starting at age 40 rather than 45 years. If the DRE is
normal and the PSA is less than1 ng/mL, then repeat testing
should occur at 2–4 year intervals. If the DRE is normal and the
PSA is between 1 and 3 ng/mL, then repeat testing should occur
at 1–2 year intervals. If the PSA is greater than 3 ng/mL or the
DRE is suspicious, then a TRUS-guided biopsy should be con-
sidered. An alternative to biopsy is to follow up in 6–12months
with a repeat PSA and DRE or determine the percent free PSA,
4Kscore, or PHI as detailed in their guidelines [55].
8.4 Colon cancer screening recommendations
Generally, patients who have a high-risk colon cancer muta-
tion should have a colonoscopy at age 20–25 years or 2 to
5 years prior to the earliest colon cancer if it is diagnosed
before age 25 years. This should be repeated every 1 to 2 years
[56]. There are, however, several more common high-risk
hereditary colon cancer syndromes including Lynch syn-
drome, familial adenomatous polyposis (FAP), and MUTYH-
associated polyposis (MAP) that have tailored follow-up.
Lynch syndrome is caused by autosomal dominantly inherited
mutations in the mismatch repair genesMLH1,MSH2, EPCAM,
MSH6, and PMS2. Individuals who carry mutations tend to form
colon polyps at an earlier age and are at a high lifetime risk for
colon cancer (up to 80%) unless frequent surveillance is done.
Other associated cancer risks include uterine and ovarian cancer
in female carriers and upperGI tumors, pancreatic cancer, urinary
tract cancer, sebaceous neoplasms, and more rarely, brain cancer.
Surveillance recommendations include colonoscopy starting at
age 25 or 2–5 years prior to the earliest diagnosed colon cancer
with follow-up every 1–2 years. There is no data to support
screening for uterine or ovarian cancer. Women can consider a
prophylactic hysterectomy and bilateral salpingo-oophorectomy
after childbearing is complete. There is no evidence to support
screening for upper GI tumors, but a baseline endoscopy at age
35 with follow-up every 3–5 years may be considered in select
families (based on FH and ethnicity). An annual urinalysis can be
done to screen for urinary tract cancers [56].
FAP is a colon cancer predisposition syndrome in which
individuals develop hundreds to thousands of precancerous
colonic polyps beginning, on average, at age 16 years (range
7–36 years). FAP is caused by autosomal dominantly
inherited mutations in the APC gene, although 20–25% of
probands have a de novo mutation. Ninety-five percent of
individuals with classic FAP will develop colon cancer by
age 35 unless a total colectomy is performed. Extracolonic
manifestations may include polyps of the gastric fundus and
duodenum, osteomas, dental anomalies, congenital hypertro-
phy of the retinal pigment epithelium (CHRPE), soft tissue
tumors, desmoid tumors, and associated cancers. There is no
known risk for melanoma in patients who have FAP.
Attenuated FAP is characterized by an increased risk for
colon cancer but fewer colon polyps, more proximally located
polyps, and diagnosis of colon cancer at a later age.
Gardner syndrome is characterized by polyposis typical of
FAP together with osteomas and soft tissue tumors. Turcot
syndrome is the association of colon polyps and central ner-
vous system (CNS) tumors [57].
Pat ients who have classic FAP should have a
proctocolectomy or total colectomy in early teenage years
with follow-up surveillance of any remaining bowel every
1–3 years. Surveillance for thyroid cancer by annual thyroid
exam stating in teenage years as well as upper endoscopy
starting at age 20–25 is recommended. Patients who have
attenuated familial adenomatous polyposis (AFAP) may be
managed more conservatively with frequent colonoscopies if
the polyp burden is manageable [56].
MUTYH-associated polyposis is caused by biallelic muta-
tions in theMUTYH gene and tends to have a similar number
of polyps as patients who have AFAP. Thus, genetic testing for
both should be done in a patient who has greater than 20
polyps. Duodenal adenomas are found in 17–25% of individ-
uals with MAP. Patients may also have serrated adenomas,
hyperplastic/sessile serrated polyps, and mixed (hyperplastic
and adenomatous) polyps. Frequency of colonoscopy and en-
doscopy depends on age and polyp load. A modestly in-
creased risk for rather late-onset malignancies of the ovary,
bladder, and skin is suspected, and there is some evidence
for an increased risk for breast and endometrial cancer, but
currently, there are no recommendations for surveillance [56].
8.5 Pancreatic cancer screening recommendations
An international consortium panel released a consensus sum-
mary in 2013 on the management of high-risk individuals.
86 Cancer Metastasis Rev (2017) 36:77–90
There was general agreement that endoscopic ultrasonogra-
p h y ( EUS ) a n d / o r MR I /m a g n e t i c r e s o n a n c e
cholangiopancreatography should be utilized for initial
screening. Screening is recommended for high-risk individ-
uals, including patients with a family history of pancreatic
cancer or patients with an STK11, CDKN2A/p16, or a
BRCA2 mutation with ≥1 affected first-degree relative.
However, consensus was not reached for the age to initiate
screening or to stop surveillance. At our institution, we start
at 45 years of age or 10 years younger than the youngest
diagnosed family member, whichever is younger. More evi-
dence is needed, particularly for how to manage patients with
detected lesions. Screening and subsequent management
should take place at high-volume centers with multidisciplin-
ary teams, preferably within research protocols [58].
8.6 Other cancer screening recommendations
Melanoma syndromes have also been associated with uveal
melanoma, renal cell carcinoma, astrocytoma, and other neu-
rological cancers, mesothelioma and paraganglioma. Any
pedigree that carries a mutation that overlaps with cancer pre-
disposition genes for these syndromes or that has these types
of cancers in the pedigree needs to be monitored carefully for
signs and symptoms of these cancers. For example, ophthal-
mologic examinations should be performed every 6–
12 months in BAP1mutation carriers. BAP1mutation carriers
should also be explicitly warned about asbestos exposures,
given their predisposition toward mesothelioma. Screening
MRIs annually may be warranted if the pedigree or causative
mutation is associated with multiple internal malignancies.
There are a larger number (variety) of cancers associated
with Li Fraumeni including risks for childhood cancers. There
are published guidelines for surveillance as well as significant
controversy regarding the frequency of surveillance as well as
the optimal modality [59].
9 Conclusion
BPrecision medicine^ promises the use of an individual’s per-
sonal genome combined with a molecular analysis of that
individual’s diseased tissue to identify rational therapies for
that individual. The use of personal genomic information prior
to the development of disease permits tailored surveillance
recommendations, which may improve prevention and early
detection, simultaneously reduce costs of care, and increase
societal productivity. Our institutions have implemented panel
testing for melanoma-dominant and melanoma-subordinate
syndromes in order to provide state-of-the art care for these
high-risk individuals as well as to promote further understand-
ing of the spectrum of these syndromes.
The field of cancer genetics is quickly moving from a de-
scriptive era, in which predisposition is defined primarily by
disease phenotypes, into a whole-genome era, in which the
relative contributions of high- and low-penetrance mutations,
polymorphisms of modifier genes, and environmentally-
induced somatic mutations are understood. During this transi-
tion period, patient care must be adjusted to keep pace with—
and support further development of—the science of genetic
predisposition.
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